Minibody-Based and scFv-Based Antibody Fragment-Drug Conjugates Selectively Eliminate GD2-Positive Tumor Cells
International Journal of Molecular Sciences · 2023
DOI: 10.3390/ijms24021239 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Molecular Sciences, 2023. Verfasst von Daniel V Kalinovsky und 10 weiteren Autor:innen. Beteiligte Einrichtung: Shemyakin-Ovchinnikov Institute of Bioorganic Chemistry, Russian Academy of Sciences, 117997 Moscow, Russia. Hauptthemen laut MEDLINE: Antineoplastic Agents, Immunoconjugates, Neuroblastoma. Die Arbeit wurde bisher 33-mal zitiert (Crossref) und nennt 41 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Russian Science Foundation.
Abstract (Originalsprache)
Ganglioside GD2 is a well-established target expressed on multiple solid tumors, many of which are characterized by low treatment efficiency. Antibody-drug conjugates (ADCs) have demonstrated marked success in a number of solid tumors, and GD2-directed drug conjugates may also hold strong therapeutic potential. In a recent study, we showed that ADCs based on the approved antibody dinutuximab and the drugs monomethyl auristatin E (MMAE) or F (MMAF) manifested potent and selective cytotoxicity in a panel of tumor cell lines and strongly inhibited solid tumor growth in GD2-positive mouse cancer models. Here, we employed two different GD2-binding moieties–minibodies and scFv fragments that carry variable antibody domains identical to those of dinutuximab, and site-directly conjugated them to MMAE or MMAF by thiol-maleimide chemistry with drug-to-antibody ratios (DAR) of 2 and 1, respectively. Specific binding of the antibody fragment-drug conjugates (FDCs) to GD2 was confirmed in direct ELISA, flow cytometry, and confocal microscopy. Selective cytotoxic and cytostatic effects of the conjugates were observed in GD2-positive but not GD2-negative neuroblastoma and melanoma cell lines. Minibody-based FDCs demonstrated more pronounced cytotoxic effects and stronger antigen binding compared to scFv-based FDCs. The developed molecules may offer considerable practical benefit, since antibody fragment-drug conjugates are capable of enhancing therapeutic efficacy of ADCs by improving their pharmacokinetic characteristics and reducing side effects.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Shemyakin-Ovchinnikov Institute of Bioorganic Chemistry, Russian Academy of Sciences, 117997 Moscow, Russia.
- Orekhovich Institute of Biomedical Chemistry, 119121 Moscow, Russia.
- Dmitry Rogachev Federal Research Center of Pediatric Hematology, Oncology and Immunology, 117997 Moscow, Russia.
- Real Target LLC, 108841 Moscow, Russia.
- Lomonosov Moscow State University, 119991 Moscow, Russia.
- Sechenov First Moscow State Medical University, 119992 Moscow, Russia.
ORCID-Profile: Daniel V Kalinovsky, Irina V Kholodenko, Elena V Svirshchevskaya, Dmitriy Y Ryazantsev, Maria V Konovalova, Sergey S Larin, Sergey M Deyev, Roman V Kholodenko
Förderung
- Russian Science Foundation
Zitieren
APA
Kalinovsky, D. V., Kholodenko, I. V., Kibardin, A. V., Doronin, I. I., Svirshchevskaya, E. V., Ryazantsev, D. Y., Konovalova, M. V., Rozov, F. N., Larin, S. S., Deyev, S. M., & Kholodenko, R. V. (2023). Minibody-Based and scFv-Based Antibody Fragment-Drug Conjugates Selectively Eliminate GD2-Positive Tumor Cells. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms24021239
Vancouver
Kalinovsky DV, Kholodenko IV, Kibardin AV, Doronin II, Svirshchevskaya EV, Ryazantsev DY, et al. Minibody-Based and scFv-Based Antibody Fragment-Drug Conjugates Selectively Eliminate GD2-Positive Tumor Cells. International Journal of Molecular Sciences. 2023. doi:10.3390/ijms24021239
BibTeX
@article{Kalinovsky2023,
author = {Kalinovsky, Daniel V and Kholodenko, Irina V and Kibardin, Alexey V and Doronin, Igor I and Svirshchevskaya, Elena V and Ryazantsev, Dmitriy Y and Konovalova, Maria V and Rozov, Fedor N and Larin, Sergey S and Deyev, Sergey M and Kholodenko, Roman V},
title = {Minibody-Based and scFv-Based Antibody Fragment-Drug Conjugates Selectively Eliminate GD2-Positive Tumor Cells},
journal = {International Journal of Molecular Sciences},
year = {2023},
doi = {10.3390/ijms24021239}
}
EUVIMED